Posted by Michael Wonder on 04 Nov 2021
ICER publishes evidence report on tezepelumab for severe asthma
4 November 2021 - Tezepelumab reduces asthma exacerbations, but there is uncertainty about long-term safety as with all new biologic therapies; tezepelumab would achieve common thresholds for cost-effectiveness if priced between $9,000 – $12,100 per year.
The Institute for Clinical and Economic Review today posted its revised evidence report assessing the comparative clinical effectiveness and value of tezepelumab (Amgen, AstraZeneca) for the treatment of severe asthma.
